Research ArticleArticle
Open Access
Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases
Glen S. Hazlewood, Jordi Pardo Pardo, Cheryl Barnabe, Orit Schieir, Claire E.H. Barber, Sasha Bernatsky, Ines Colmegna, Carol Hitchon, Mark Loeb, Dominik Mertz, Laurie Proulx, Dawn P. Richards, Rosie Scuccimarri, Peter Tugwell, Holger J. Schünemann, Reza D. Mirza, Alan L. Zhou, Roko P.A. Nikolic, Megan Thomas, Helena Chase, Maede Ejaredar and Robby Nieuwlaat
The Journal of Rheumatology May 2021, jrheum.210288; DOI: https://doi.org/10.3899/jrheum.210288
Glen S. Hazlewood
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Jordi Pardo Pardo
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Cheryl Barnabe
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Orit Schieir
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Claire E.H. Barber
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Sasha Bernatsky
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Ines Colmegna
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Carol Hitchon
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Mark Loeb
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Dominik Mertz
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Laurie Proulx
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Dawn P. Richards
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Rosie Scuccimarri
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Peter Tugwell
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Holger J. Schünemann
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Reza D. Mirza
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Alan L. Zhou
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Roko P.A. Nikolic
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Megan Thomas
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Helena Chase
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Maede Ejaredar
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
Robby Nieuwlaat
G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, C. Barnabe, MD, MSc, Associate Professor of Medicine, C.E. Barber, MD, PhD, Assistant Professor of Medicine, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, and Arthritis Research Canada, Richmond, British Columbia; J.P. Pardo, LDO, Managing Editor, Centre for Global Health, University of Ottawa, Ottawa, Ontario; O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario; S. Bernatsky, MD, PhD, Professor of Medicine, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Quebec; I. Colmegna, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec; C. Hitchon, MD, MSc, Associate Professor of Medicine, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; M. Loeb, MD, MSc, Professor, D. Mertz, MD, MSc, Associate Professor of Medicine, H.J. Schünemann, MD, MSc, PhD, Professor of Medicine and Clinical Epidemiology, Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster GRADE Centers, Hamilton; L. Proulx, B.Com, D.P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario; R. Scuccimarri, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, McGill University, Montreal, Quebec; P. Tugwell, MD, Professor of Medicine, A.L. Zhou, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario; R.D. Mirza, MD, Department of Medicine, University of Toronto, Toronto, Ontario; R.P. Nikolic, BSc, Cumming School of Medicine, University of Calgary, Calgary, Alberta; M. Thomas, BHSc, M. Ejaredar, PhD, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; H. Chase, University of Ottawa, Ottawa, Ontario; R. Nieuwlaat, MSc, PhD, Associate Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. JPP has received funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. CB has received honoraria for advisory boards (Gilead, Pfizer) and speaker fees (Sanofi, Novartis) in the past 3 years and was a nonvoting member of the guidelines panel. ML has received payment for advisory boards (Pfizer, Medicago, Sanofi, Seqirus) and data safety monitoring committee (CanSino Biologics), and was a nonvoting member of the guidelines panel. LP serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies, and has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event). DPR serves as volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DPR's employer, Five02 Labs Inc., has received payment in the last 3 years from NovoNordisk (speaking about arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board). CH has received research funds from Research Manitoba, Health Sciences Centre Foundation, Pfizer, and UCB Canada for unrelated work, and was a nonvoting member of the guidelines panel. HJS serves as co-chair for the GRADE Working Group, has received funding from the Canadian Institutes of Health Research (CIHR; FRN VR4-172741), and was a nonvoting technical expert. The remaining authors report no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 14, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases
Glen S. Hazlewood, Jordi Pardo Pardo, Cheryl Barnabe, Orit Schieir, Claire E.H. Barber, Sasha Bernatsky, Ines Colmegna, Carol Hitchon, Mark Loeb, Dominik Mertz, Laurie Proulx, Dawn P. Richards, Rosie Scuccimarri, Peter Tugwell, Holger J. Schünemann, Reza D. Mirza, Alan L. Zhou, Roko P.A. Nikolic, Megan Thomas, Helena Chase, Maede Ejaredar, Robby Nieuwlaat
The Journal of Rheumatology May 2021, jrheum.210288; DOI: 10.3899/jrheum.210288
Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases
Glen S. Hazlewood, Jordi Pardo Pardo, Cheryl Barnabe, Orit Schieir, Claire E.H. Barber, Sasha Bernatsky, Ines Colmegna, Carol Hitchon, Mark Loeb, Dominik Mertz, Laurie Proulx, Dawn P. Richards, Rosie Scuccimarri, Peter Tugwell, Holger J. Schünemann, Reza D. Mirza, Alan L. Zhou, Roko P.A. Nikolic, Megan Thomas, Helena Chase, Maede Ejaredar, Robby Nieuwlaat
The Journal of Rheumatology May 2021, jrheum.210288; DOI: 10.3899/jrheum.210288